You are browsing articles on the topic of Heart Failure Archives - CardioExchange

Avatar of Behnood Bikdeli, M.D.

Heart Failure Readmissions: Neighborhood Factors Matter, Too (13 Oct 2014)

Voices

Behnood Bikdeli, M.D.

For two decades, investigators have been studying the association between neighborhood characteristics and cardiovascular disease. A landmark study from 2001 showed that living in a socioeconomically disadvantaged neighborhood was associated with higher incidence of coronary artery disease. Several studies have also shown an association between neighborhood characteristics, most notably the socioeconomic status (SES) and outcomes…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Clyde Yancy, MD

The Implications of PARADIGM-HF for Clinical Practice (29 Sep 2014)

Voices

Clyde Yancy, MD and Mary Norine Walsh, MD

Clyde Yancy and Mary Norine Walsh offer their perspectives on the much-discussed PARADIGM-HF trial.

Avatar of Benjamin Scirica, MD MPH

New Observations on Saxagliptin (15 Sep 2014)

Voices

Benjamin Scirica, MD MPH

Benjamin Scirica discusses his study group’s new analysis of data from the SAVOR-TIMI 53 randomized, placebo-controlled trial of saxagliptin in patients with type 2 diabetes.

Avatar of Boback

Race and Ethnicity Do Not Affect the Benefits of Device Therapy in Heart Failure (11 Sep 2014)

Voices

Boback Ziaeian, MD

Boback Ziaeian discusses his observational study exploring the benefits of guideline-recommended cardiac resynchronization therapy and ICD therapy in heart failure patients, according to race and ethnicity.

Avatar of CardioExchange Editors, Staff

Perspectives on PARADIGM-HF (5 Sep 2014)

Voices

CardioExchange Editors, Staff

The Editors present a distillation of reader comments on a popular post.

Avatar of Vinay

Let’s Take a Close Look at PARADIGM-HF (1 Sep 2014)

Voices

Vinay Prasad, MD MPH

Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.

Avatar of Larry Husten, PHD

SIGNIFY Trial Provokes Sound and Fury Over Controversial Drug (31 Aug 2014)

News

The already controversial drug ivabradine just got a little more controversial. The drug, which is marketed by Servier under the brand names of Corlentor and Procoralan, is available in Europe and elsewhere and is used for the treatment of heart failure and stable angina. The drug is not available in the U.S., but it is under development by Amgen for a…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of John McMurray, MbChB MD

Will There Be a PARADIGM Shift in Treatment of Heart Failure? (30 Aug 2014)

Voices

John McMurray, MbChB MD and Milton Packer, MD

John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.

Avatar of Larry Husten, PHD

Predicting PARADIGM-HF, or What to Expect When You’re Expecting (28 Aug 2014)

Voices

Larry Husten, PhD

Larry Husten analyzes the expectations surrounding the upcoming release of PARADIGM-HF and its centerpiece LCZ696 from the perspective of the medical field as well as the world of economics.

Avatar of John

The CardioMEMS HF System: What Do You Say to Your Patient? (14 Aug 2014)

Voices

John Ryan, MD

In this scenario based on a patient’s question about the CardioMEMS device, John Ryan asks, “What do you say to your patient?”